You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Patients with COPD have often lost 50% of their lung function by the time they experience symptoms1

Could your COPD patients benefit from a LAMA/LABA as first-line maintenance therapy?

Meet Robert

He is a 62-year-old COPD patient being treated with a short-acting bronchodilator agonist therapy (SABA) as required, but is not yet on a maintenance therapy.

Symptoms:

  • Breathlessness
  • Reduction of usual daily activities
  • No features suggestive of asthma or steroid responsiveness

Robert is starting to struggle with climbing stairs and doing household chores. He now watches television instead of going for long walks outside, or dancing with his wife.

Robert coughing

This is a fictional patient for illustrative purposes.

Meet Linda

She is a 64-year-old COPD patient being treated with a short acting bronchodilator agonist therapy (SABA) as required but is not yet on maintenance therapy.

Symptoms:

  • Shortness of breath
  • Tightness of chest
  • No features suggestive of asthma or steroid responsiveness

Linda is beginning to struggle with daily activities such as sweeping her floor or watering her plants in her front garden. She fears her constant shortness of breath will take away the one thing that makes her happiest, laughing at her husband of 30 years’ daily jokes.

Linda COPD Patient

This is a fictional character for illustrative purposes.

What maintenance therapy would you start Robert and Linda on?

See head-to-head data for Anoro Ellipta (a LAMA/LABA) vs. a LAMA, and vs. a LAMA/LABA below

PREV
NEXT

Anoro Ellipta (a LAMA/LABA) vs. tiotropium HandiHaler (a LAMA)

Lungs

In a pooled, post-hoc analysis of three 24-week RCTs in patients not on maintenance therapy (for ≥30 days before screening), Anoro Ellipta demonstrated a 2.4x greater lung function improvement vs. tiotropium HandiHaler (with an extra 146mL improvement in trough FEV1)2,3

SEE THE DATA

Anoro Ellipta (a LAMA/LABA) vs. tiotropium/olodaterol Respimat1 (a LAMA/LABA)

Lungs

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation), Anoro Ellipta demonstrated a 1.4x superior lung function improvement vs. tiotropium/olodaterol Respimat1 (with an extra 52mL improvement in trough FEV1)4

SEE THE DATA

You might also be interested in…

Head-to-head data vs. a LAMA

See data for Anoro Ellipta vs. tiotropium HandiHaler (a LAMA)

Dosing & the Ellipta device

Learn about the easy-to-use Ellipta device

Molecules

Anoro Ellipta contains umeclidinium (a LAMA) and vilanterol (a LABA)

References

  1. Sutherland ER & Cherniack RM. N Engl J Med 2004; 350:2689–2697.
  2. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
  3. GSK data on file RF/UCV/0112/15
  4. Feldman G.J et al. Adv Ther 2017; 34:2518–2533

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro is a registered trademark of the GlaxoSmithKline group of companies.

Innoviva Logo

PM-IE-UCV-WCNT-210014 June 2023